FDA Approval: Maintenance Lurbinectedin for SCLC
Update: 2025-10-07
Description
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC.
Guest:
Dr. Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Guest:
Dr. Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
